الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

ingenus pharmaceuticals, llc - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e), norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s) - estradiol and norethindrone acetate tablets are indicated for: limitation of use when prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, first consider the use of topical vaginal products. limitation of use when prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. consider estrogen therapy only for women at significant risk of osteoporosis. estradiol and norethindrone acetate tablets are contraindicated in women with any of the following conditions: • undiagnosed abnormal genital bleeding [see warnings and precautions (5.2) ]  • breast cancer or history of breast cancer [see warnings and precautions (5.2) ] • estrogen-dependent neoplasia [see warnings and precautions (5.2) ] • active dvt, pe, or history of these conditions [see warnings and precautions (5.1) ] • active arterial thromboembolic disease (for example, stroke and mi), or a history of these conditions [see warnings a

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

amneal pharmaceuticals llc - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use: the use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e. longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1) ] . the use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to medroxyprogesterone acetate injectable suspension (medroxyprogesterone acetate) or any of its other ingredients [see warnings and precautions (5.5)] . - significant liv

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

heritage pharmaceuticals inc - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 0.5 mg - estradiol tablets, usp is indicated in the: 1.treatment of moderate to severe vasomotor symptoms associated with the menopause. 2.treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. 5. treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). 6. prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology, clinical studies.) the mainstays for decreasing the risk of postmeno

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

naari pte. limited - norethindrone acetate (unii: 9s44lic7oj) (norethindrone - unii:t18f433x4s), estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol and norethindrone acetate tablets is indicated for: limitation of use when prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered. limitation of use when prescribing solely for the prevention of postmenopausal osteoporosis, first consider the use of non-estrogen medications. consider estrogen therapy only for women at significant risk of osteoporosis. estradiol and norethindrone acetate tablets are contraindicated in women with any of the following conditions: • undiagnosed abnormal genital bleeding [see warnings and precautions (5.2)] • breast cancer or history of breast cancer [see warnings and precautions (5.2)] • estrogen-dependent neoplasia [see warnings and precautions (5.2)] • active dvt, pe, or history of these conditions [see warnings and precautions (5.1)] • active arterial thromboembolic disease (for example, stroke and

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg - estradiol tablets are indicated in the: 1.    treatment of moderate to severe vasomotor symptoms associated with the menopause.  2.    treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribed solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.  3.    treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4.    treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. 5.    treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). 6.    prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate (see clinical pharmacology, clinical studies .) the mainstays for decreasing the

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

a-s medication solutions - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 150 mg in 1 ml - depo-provera ci is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use depo-provera ci long-term [see warnings and precautions (5.1) ]. the use of depo-provera ci is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to depo-provera ci (medroxyprogesterone acetate) or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.7)] . - undiagnosed vaginal bleeding [see warnings a

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg - estradiol tablets are indicated in the: - treatment of moderate to severe vasomotor symptoms associated with the menopause. - treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. when prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. - treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. - treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. - treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). - prevention of osteoporosis. when prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (see clinical pharmacology , clinical studies. ) - the mainstays for decreasing the risk of postmenopau

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

preferred pharmaceuticals, inc. - estradiol (unii: 4ti98z838e) (estradiol - unii:4ti98z838e) - estradiol 1 mg - estradiol tablets are indicated in the: estrogens should not be used in individuals with any of the following conditions:

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

teva parenteral medicines, inc. - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate 150 mg in 1 ml - medroxyprogesterone acetate injectable suspension is indicated for use by females of reproductive potential to prevent pregnancy. limitations of use : the use of medroxyprogesterone acetate injectable suspension is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate [see dosage and administration (2.1) and warnings and precautions (5.1)] . the use of medroxyprogesterone acetate injectable suspension is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)] . - known hypersensitivity to medroxyprogesterone acetate injectable suspension or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and p

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

a-s medication solutions - medroxyprogesterone acetate (unii: c2qi4ioi2g) (medroxyprogesterone - unii:hsu1c9yres) - medroxyprogesterone acetate is indicated only for the prevention of pregnancy. the loss of bone mineral density (bmd) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in bmd that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use medroxyprogesterone acetate long-term [see warnings and precautions (5.1)] . the use of medroxyprogesterone acetate is contraindicated in the following conditions: - known or suspected pregnancy or as a diagnostic test for pregnancy. - active thrombophlebitis, or current or past history of thromboembolic disorders, or cerebral vascular disease [see warnings and precautions (5.2)] . - known or suspected malignancy of breast [see warnings and precautions (5.3)]. - known hypersensitivity to medroxyprogesterone acetate or any of its other ingredients [see warnings and precautions (5.5)] . - significant liver disease [see warnings and precautions (5.6)]. - undiagnosed vaginal bleeding